Table 1. Clinical data and multiple regression analysis of PDAC patients gemcitabine-based and 5FU-based regimens.
| Baseline characteristics | All | GEM | 5FU | P value† |
|---|---|---|---|---|
| Number | 142 | 83 | 59 | |
| Gender (female) | 73 (51.4%) | 42 (50.6%) | 31 (52.5%) | 0.9541 |
| Age (years), median (range) | 68.0 (41.0–85.0) | 69.0 (41.0–85.0) | 66.0 (44.0–78.0) | 0.0472 |
| Body mass index (kg/m2), mean (SD) | 23.5 (4.1) | 23.8 (4.2) | 23.2 (4.1) | 0.487 |
| CA 19-9 (U/mL), mean (SD) | 34,783 [88,679] | 32,904 [96,349] | 38,540 [71,993] | 0.672 |
| Albumin (g/L), mean (SD) | 35.1 (6.4) | 34.4 (6.3) | 37.1 (6.5) | 0.65 |
| ECOG PS | 0.8406 | |||
| ECOG [0–1] | 102 (72%) | 61 (73%) | 41 (70%) | |
| ECOG [2+] | 34 (28%) | 19 (27%) | 15 (30%) | |
| Monocyte count (per µL), median (range) | 0.63 (0.0–1.85) | 0.61 (0.0–1.53) | 0.69 (0.38–1.85) | 0.344 |
| Tumor localization‡, n (%) | 0.1476 | |||
| Head | 58 (41%) | 40 (48%) | 18 (30%) | |
| Body | 53 (37%) | 31 (37%) | 22 (37%) | |
| Tail | 44 (31%) | 22 (26%) | 22 (37%) |
†, the Fisher exact test or Chi-squared test was used for comparison of qualitative variables between GEM and 5FU groups; analysis of variance was used for comparison of quantitative variables; ‡, patients presenting tumors in more than one location are included in both categories, BACAP cohort had missing data. Note: the sum of the percentages might not be equal to 100% or sum of patient might not be equal to their total if data were not available. PDAC, pancreatic ductal adenocarcinoma; 5FU, 5-fluorouracil; All, all patients included; GEM, patient subgroup treated with Gem-based chemotherapy as first line; 5FU, patient subgroup treated with 5FU-based chemotherapy; SD, standard deviation; CA19-9, carbohydrate antigen 19-9; ECOG PS, Eastern Cooperative Oncology Group Performance Status.